BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor-pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (Trial in progress) Meeting Abstract
| Authors: | Hill, M.; Sharman, J. P.; Jurczak, W.; Coombs, C. C.; Wang, D.; Ku, N. C.; Guntur, A.; Shahda, S.; Leow, C. C.; Ghia, P.; Mato, A. R. |
| Abstract Title: | BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor-pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (Trial in progress) |
| Meeting Title: | 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | clinical trial; cll; chronic lymphocytic leukemia; pirtobrutinib; trial-in-progress; btki |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Sep 28-Oct 1 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S265 |
| End Page: | S266 |
| Language: | English |
| ACCESSION: | WOS:000897948100202 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(22)01323-4 |
| Notes: | Meeting Abstract: CLL-114 -- Source: Wos |
